Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers
- PMID: 19818148
- PMCID: PMC2771044
- DOI: 10.1186/1471-2407-9-360
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers
Abstract
Background: BRCA1 gene-related tumours are more frequently estrogen receptor (ER) and progesterone receptor (PR) negative with a lower prevalence of human epidermal growth factor receptor 2 (HER2) overexpression or amplification. We evaluated the effectiveness of a combination of homogeneously selected criteria and immunohistochemical (IHC) characteristics of Familial Breast Cancers (FBCs) in detecting BRCA1 mutation carriers.
Methods: Primary breast tumours from 93 FBC patients defined by specific eligibility criteria, based on personal and familial tumour history, were evaluated by Allred's method. The BRCA1 molecular analysis, including Multiplex Ligation-dependent Probe Amplification (MLPA), was considered as the gold standard assay.
Results: A total of 10 BRCA1 pathogenetic mutations was found. With the exclusion of the tumours characterized by double positive receptorial status and/or strong HER2 positivity (3+), we identified 22 patients, 10 of whom resulted as BRCA1 mutation carriers. The sensitivity, specificity, positive and negative predictive values were 100%, 83.3%, 45.4% and 100% respectively.
Conclusion: Our findings suggest that the IHC analysis by Allred's method improves our ability to select patients for BRCA1 testing.
Similar articles
-
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.Breast Cancer Res. 2008;10(1):R17. doi: 10.1186/bcr1863. Epub 2008 Feb 14. Breast Cancer Res. 2008. PMID: 18275599 Free PMC article.
-
Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.Mod Pathol. 2008 Oct;21(10):1262-70. doi: 10.1038/modpathol.2008.43. Epub 2008 Mar 7. Mod Pathol. 2008. PMID: 18327210
-
Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.BMC Cancer. 2019 Jul 15;19(1):695. doi: 10.1186/s12885-019-5908-6. BMC Cancer. 2019. PMID: 31307407 Free PMC article.
-
A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.Clin Lab Med. 2023 Jun;43(2):299-321. doi: 10.1016/j.cll.2023.03.004. Clin Lab Med. 2023. PMID: 37169447 Review.
-
A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.Surg Pathol Clin. 2022 Mar;15(1):105-120. doi: 10.1016/j.path.2021.11.007. Epub 2022 Jan 31. Surg Pathol Clin. 2022. PMID: 35236627 Review.
References
-
- Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, Vijver M van der, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF. Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175–5180. doi: 10.1158/1078-0432.CCR-04-2424. - DOI - PubMed
-
- Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10:2029–2034. doi: 10.1158/1078-0432.CCR-03-1061. - DOI - PubMed
-
- Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16:1642–1649. - PubMed
-
- Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001;7:1937–1945. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous